- Home
- STHO vs NTHI Comparison
STHO vs NTHI Comparison
Compare STHO & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STHO | NTHI |
|---|---|---|
| Founded | 2022 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.0M | 114.6M |
| IPO Year | 2022 | 2023 |
Fundamental Metrics
Financial Performance| Metric | STHO | NTHI |
|---|---|---|
| Price | $9.49 | $4.30 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 14.1K | ★ 61.6K |
| Earning Date | 05-08-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.73 | N/A |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $110,143,000.00 | $39,990.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $3.67 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.08 | $3.01 |
| 52 Week High | $9.78 | $12.99 |
Technical Indicators
Market Signals| Indicator | STHO | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 56.45 | 43.36 |
| Support Level | $8.71 | $3.01 |
| Resistance Level | $9.68 | $3.70 |
| Average True Range (ATR) | 0.24 | 0.22 |
| MACD | 0.01 | 0.05 |
| Stochastic Oscillator | 50.00 | 43.75 |
Price Performance
Historical ComparisonAbout STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties, and land and development properties.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.